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Abstract
Background: The serine/threonine kinase PIM2 is highly expressed in human leukemia and lymphomas and has been
shown to positively regulate survival and proliferation of tumor cells. Its diverse ATP site makes PIM2 a promising target for
the development of anticancer agents. To date our knowledge of catalytic domain structures of the PIM kinase family is
limited to PIM1 which has been extensively studied and which shares about 50% sequence identity with PIM2.
Principal Findings: Here we determined the crystal structure of PIM2 in complex with an organoruthenium complex
(inhibition in sub-nanomolar level). Due to its extraordinary shape complementarity this stable organometallic compound is
a highly potent inhibitor of PIM kinases.
Significance: The structure of PIM2 revealed several differences to PIM1 which may be explored further to generate isoform
selective inhibitors. It has also demonstrated how an organometallic inhibitor can be adapted to the binding site of protein
kinases to generate highly potent inhibitors.
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Introduction
The PIM2 kinase belongs to a family of three serine/threonine
kinases (PIM1-3) first identified as preferential proviral insertion sites
in Moloney Murine Leukemia Virus (MoMuLV) induced T-cell
lymphomas [1,2]. In humans PIM2 has been implicated in the
transformation of both T and B lymphocytes and is highly expressed in
human leukemia and lymphomas [3]. Importantly, expression of the
pim2 transgene predisposes mice to T-cell lymphomas and is highly
cooperative with the Em-myc transgene in the development of pre-B cell
l e u k a e m i a[ 4 ] .L o c a t e do nt h eXc h r o m o s o m et h ep i m 2g e n ei sh i g h l y
induced by growth factors and cytokines through STAT5 activation.
Indeed its downstream activation by oncogenes including JAK2,
v-ABL and FLT3-ITD appears essential for their ability to drive
tumorigenesis [5–7]. For example, cells transformed by FLT3 or
BCR/ABL mutations that confer resistance to small-molecule
inhibitors remain sensitive to PIM2 knockout by RNAi [8].
PIM kinases confer a growth advantage through a variety of
mechanisms. They promote growth factor-independent prolifera-
tionbyphosphorylationofcellcyclefactorssuch asp21
Cip1/Waf1[9],
cdc25A [10] and eIF4e-BP1 [11]. They protect cells from apoptosis
by phosphorylation of the pro-apoptotic protein BAD [12]. The
PIM1 kinase has also been shown to phosphorylate an ABC
transporter [13] promoting drug efflux and to co-activate MYC-
target genes by phosphorylation of histone H3 serine 10 [14]. PIM2
also confers resistance to rapamycin indicating a parallel signaling
pathway from the PI3K/Akt/TOR cascade [11,15].
The PIM2 kinase has therefore emerged as a key drug target to
restore apoptosis in drug resistant human cancers [16]. To date
structural information for the PIM kinase family is restricted to
PIM1 for which the majority of inhibitor development has also
been directed [17–20]. Interestingly, PIM kinases have an altered
hinge region which does not allow the formation of two hydrogen
bonds to ATP typically present in protein kinase ATP complexes.
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(ERPXPX) removes the typical +3 hydrogen bond donor of the
hinge backbone resulting in considerably high Km values for ATP.
Inhibitors often mimic these hydrogen bonds leading to consid-
erable cross-reactivity with other kinases that all share this active
site feature. Thus, the considerably different active site of PIM
kinases provides potential for the design of PIM-specific inhibitors.
Subsequently, a series of imidazo[1,2-b]pyridazine inhibitors was
identified with anti-leukemic activity that bound PIM1 in an ATP
competitive but non-ATP mimetic manner [21]. Surprisingly,
PIM2 was markedly less susceptible to inhibition than PIM1.
We have developed a series of metal complexes inspired by the
staurosporine scaffold [22] that enable us to expand the available
small molecule chemical space and identify new inhibitors of
PIM2. In the designed organoruthenium complexes the coordi-
nate bonds are proven to be kinetically inert and are therefore
likely to be stable in vivo thus avoiding metal-related toxicity.
Here, we describe the crystal structure of human PIM2 bound to
one of these inhibitors, the (R)-enantiomer of compound 1 (Fig. 1).
In combination with our inhibition data, the structure and
specificity profiles highlight the view of the metal centre as a
‘‘hypervalent carbon’’ and further extend structural opportunities
for inhibitor design.
Results
Overview of the PIM2 structure
The PIM2 protein crystallized in spacegroup H3 with two
protein molecules per asymmetric unit and was refined to 2.8 A ˚
resolution (see Table 1 for data collection and refinement
statistics). Overall, PIM2 shows the typical bilobal kinase
architecture with a constitutively active closed conformation.
The main chain of both molecules is identical with the exception
of two flexible regions in the N-terminal lobe. At the N-terminus
residues Gly22 to Glu31 which are disordered in molecule A form
a short helix in molecule B while the loop preceding the aC helix is
disordered in molecule B (Asn66 to Val78), but partially ordered in
molecule A. In addition, the tip of the adjacent b4-b5-loop is not
defined in either molecule (Fig. 2).
Structural differences between PIM1 and PIM2
Human PIM2 shares 55% sequence identity with PIM1.
Overall the PIM2 structure is similar to the closely related PIM1
s t r u c t u r e( P D B2 B Z H ,[ 2 3 ] ) with the main chain atoms
superimposing with an r.m.s.d. of 0.9 A ˚. The PIM1 hinge-region
sequence ERPEPV is conservatively replaced by ERPLPA and
both kinases lack the typical +3 hydrogen bond donor. The
activation loops also show similar active conformations with a
conserved aspartate (PIM2 Asp196) mimicking the phosphory-
lated Thr288 in active Aurora-A (Fig. 3). In PIM2 both the
Asp196 and Asp198 side chains form salt bridge interactions with
Arg162 from the catalytic HRD motif, although this side chain
was disordered in molecule A. The activation segment is also
stabilized by hydrogen bonds formed between Tyr194 and the
Figure 1. Staurosporine as an inspiration for the design of
organoruthenium complexes 1–15. Shown is the (R)-isomer.
doi:10.1371/journal.pone.0007112.g001
Table 1. Crystallographic data and refinement statistics.
Data collection pdb-code: 2IWI
Space group H3
Cell dimensions [A ˚] a=154.770, b=154.770, c=78.600
Resolution [A ˚]2 . 8
Unique reflections 16017
Completeness** 99.69 (95.2)
Rmerge 4.9%
I/s** 21.0 (2.1)
Refinement
Rwork (Rfree*) (%) 24.4/28.9
Rmsd bond length [A ˚] 0.012
Rmsd bond angle [
o] 1.265
Average B-factor (A ˚2) 35.2
Protein atoms 3687
Other 95
Ramachandran
allowed [%] 91.1
generously allowed [%] 8.9
dissallowed [%] 0
*using randomly selected 5% of data.
**values in last shell shown in brackets.
doi:10.1371/journal.pone.0007112.t001
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between Asp192 and the side chain of His190. However, the salt
bridge between the conserved aC Glu83 and the active site lysine
(Lys61) is not observed due to disorder of the lysine side chain.
Substrate binding residues identified from the structure of PIM1
in complex with a consensus peptide (RRRHPSG) [24] are also
strictly conserved in PIM2 consistent with their overlapping
substrate specificity.
The most significant difference between PIM1 and PIM2 is the
absence of the C-terminal aJ helix in PIM2 (Fig. 2A). The last 23
residues of PIM2 share little sequence identity with PIM1 and are
disordered. This PIM2 region contains 6 proline residues and is
not predicted to form helical structure. In PIM1 aJ packs below
the b8-b9-loop and the absence of this interaction might increase
flexibility in PIM2 within the N-terminal kinase lobe and
contribute to the disordered regions of the PIM2 structure. One
of these regions, the loop preceding helix aC, forms an unusual b-
hairpin in PIM1 (Fig. 2B). Some dozen residues are present in this
insertion in all three PIM kinases and the partial structure present
in PIM2 molecule A suggests a similar architecture. Additionally,
the loop following aC in both PIM2 and PIM3 contains a two-
residue insertion relative to PIM1 which changes the loop
conformation. In PIM2 this loop is potentially destabilized by
the sequence G-A-G-G-G which may further increase flexibility in
the N-terminal lobe.
Inhibitor synthesis and design
The organoruthenium complexes mimic the highly potent
inhibitor staurosporine with a distinctive globular structure more
similar to the shape of the kinase ATP pocket than many planar
kinase inhibitors. The indolocarbazole alkaloid scaffold is replaced
with a simple metal complex that retains the main features of the
indolocarbazole aglycon in a metal-chelating pyridocarbazole
ligand while the carbohydrate is replaced by a ruthenium
fragment. Utilizing new chemical space, this scaffold has shown
remarkable specificity for the PIM1 kinases [23] and glycogen
synthase kinase 3 (GSK-3) [25].
Binding mode of compound 1
The structure of PIM2 in complex with the (R)-enantiomer of
compound 1 [23,26] shows the perfect fit of the inhibitor to the
ATP pocket (Fig. 4). As designed the metal centre does not form
any direct interactions with the kinase domain but plays a
structural role organizing the organic ligands in the three-
dimensional space. Overall, the binding mode is conserved
compared to the structure of PIM1 in complex with the same
inhibitor (2BZH) [23]. The hinge region proline (Pro119) restricts
PIM2 to the formation of only one hydrogen bond with ATP and
ATP mimetic inhibitors. As expected, the maleimide of compound
1 establishes one hydrogen bond between the imide NH and the
backbone carbonyl oxygen of Glu117. An additional water-
mediated hydrogen bond in the equivalent PIM1-inhibitor
complex between the maleimide carbonyl and the backbone
amide of Glu186 from the DFG motif (PIM2 Glu182) is not
observed in PIM2, but could reflect the lower resolution of the
structure.
A key feature of both the PIM1 and PIM2 complexes is the close
contact of the CO ligand with the glycine rich loop (the distance in
PIM2 between the Gly39 carbon alpha and the CO group is just
3.1 A ˚) in which Gly39 together with Val46 and Phe43 in PIM2
Figure 2. Overall structure of PIM2 and comparison with PIM1. Overlay of the two proteins (shown in ribbon representation) reveals the
strong conservation of the kinase fold. A. PIM1 (2bzh, coloured orange) contains the C-terminal aJ helix that is absent in PIM2 (coloured green for b-
strand and red for a-helix). B. The view is rotated by 90u to highlight the unusual b-hairpin in the kinase N-lobe which is partially disordered in the
PIM2 structure.
doi:10.1371/journal.pone.0007112.g002
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binding of the inhibitor is further explained by the close
hydrophobic packing on the N-terminal lobe face from Leu38,
Phe43, Val46, Ala59 and Leu116 and on the opposite face from
Ile100, Ala122, Leu170, Ile181. All of these residues are conserved
in PIM1 with the exception of Ala122 which is replaced by Val126
in PIM1. This results in a small increase in the inhibitor packing
distance which is 3.5 A ˚ from the PIM1 valine side chain and 4.0 A ˚
from the PIM2 alanine. The adjacent hinge substitution from
PIM1 Glu124 to PIM2 Leu120 could also introduce a subtle
change in the dynamics of the PIM hinge region, but does not
change the hinge structure. This region contains a two-residue
insertion relative to most kinases and consequently makes no
interaction with the inhibitor.
Structure-activity relationship (SAR) of Ru-based
inhibitors
The scaffold of compound 1 was further explored with an
additional 14 derivatives [27] (Fig. 1) and SAR was performed
against PIM1 and PIM2 using a radiolabeled in vitro phosphor-
ylation assay (Fig. 5). In the presence of either staurosporine or the
crystallized inhibitor 1 PIM2 retained ,70% activity at an
inhibitor concentration of 10 nM. The SAR suggests that the
addition of potential hydrogen bonding groups at the R1 and R2
positions dramatically increases potency against both kinases.
Similar substitution of the R3 position was less effective and
halogen substitution was even more disruptive. The majority of
compounds were slightly more potent against PIM1 than PIM2.
However, the most potent inhibitor for PIM2, compound 12,
Figure 3. Activation loop structure in PIM2. Residues stabilizing a constitutively active loop conformation via hydrogen bonding are shown in
stick representation.
doi:10.1371/journal.pone.0007112.g003
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10 nM, was marginally less effective against PIM1.
Discussion
The proto-oncogene PIM2 is a key mediator of hematopoietic
cell growth and apoptotic resistance and complements transfor-
mation by c-MYC and mutant tyrosine kinases including BCR/
ABL and FLT3-ITD. Importantly, PIM2 inactivation can restore
apoptosis to otherwise drug-resistant cancers and is therefore an
attractive therapy to supplement current drug regimes such as
Gleevec
TM. The structure of PIM2 reveals a constitutively active
conformation consistent with the view that PIM2 activity is
regulated principally at the transcriptional level [11]. Consequent-
ly, the oncogenic potential of PIM2 is greatly increased on
overexpression.
Overall, the structure is highly similar to PIM1, particularly in
the ATP pocket which is nearly completely conserved in
comparison to the overall sequence identity of 55%. The generally
reduced susceptibility of PIM2 to previously characterized PIM1
inhibitors such as LY3319531 [28] might instead result from a
change in protein dynamics as suggested here by several
disordered loops in the N-terminal kinase lobe. The main
structural distinction between the two kinases is the absence of
the aJ helix in PIM2 which removes a significant stabilizing
interaction close to the interface between the N and C-terminal
lobes as well as differences in the kinase hinge and P loop residues.
Based on the initial staurosporine scaffold the organoruthenium
complexes have provided marked specificity for the GSK3 and
PIM kinases by the introduction of the metal centre coordinated
by a cyclopentadienyl ring and a CO ligand [23,25,26]. The
structures of PIM1 and now PIM2 bound to 1 show a remarkable
fit between the inhibitor and the ATP pocket that explains the
inhibitor’s potency. Our SAR analysis highlights the promise for
further scaffold optimization with both kinases having particular
preference for a hydroxyl substituent at the R1 position
(compound 2) [27,29]. The structure of PIM1 in complex with
compound 2 showed similar positions for the maleimide group, the
cyclopentadienyl ring and the CO ligand, but a 180u flip in the
pyridocarbazole moiety that enables two water-mediated hydro-
gen bonds to form through the R1 hydroxyl with Glu89 [23].
This flexibility indicates further opportunity for inhibitor
derivatisation and indeed PIM2 was inhibited most strongly by
compound 12 containing an additional carboxyl group at the R2
Figure 4. Inhibitor interactions in the ATP pocket. The surface of the ATP pocket is shown in transparent green. The electron density (2FoFc,
contoured at 1s level) for inhibitor 1 is shown in orange.
doi:10.1371/journal.pone.0007112.g004
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in two conformations (PDB 2J2I [28]) and the imperfect fit may
partially explain its ineffectiveness against PIM2. The primary
LY3319531 conformation makes close contact with PIM1 Val126
(3.3 A ˚) and the subtle change to Ala122 in PIM2 may be sufficient
to destabilize this binding mode. The PIM kinases contain a two-
residue insertion in the hinge preceding this position and the
smaller PIM2 side chain may allow greater exploitation of this
available space.
Mouse knockouts lacking all three PIM genes remain viable and
fertile but show reduced body size with no hematopoietic response
to growth factors [30]. The PIM2 structure and inhibitor data
presented here provide further direction to develop well-tolerated
drug molecules that stop growth factor independence, limit drug
resistance and induce tumour apoptosis.
Materials and Methods
Protein expression and purification
Full length human PIM2 (34 kD isoform, gi 42821112) was
subcloned by ligation-independent cloning into a pET-derived
expression vector, pLIC, and expression performed in BL21(DE3)
with 0.15 mM isopropyl 1-thio-b-D-galactopyranoside induction
for 4 h at 18uC. Cells were lysed using a high pressure
homogenizer and cleared by centrifugation, and the lysate was
purified by nickel-sepharose chromatography. The eluted PIM2
protein was treated with l-phosphatase together with tobacco etch
virus (TEV) protease overnight to remove phosphorylation and the
hexahistidine tag, respectively. The protein was further purified on
a Mono Q column and by size exclusion chromatography. The
eluted protein was homogeneous and non-phosphorylated as
shown by ESI-MS. PIM2 protein was stored at 4uC in elution
buffer (50 mM HEPES, pH 7.5, 250 mM NaCl) with 10 mM
DTT or frozen in liquid nitrogen and stored at 280uC. Typical
crystals had dimensions of 156565 mm
3.
Crystallization and Structure Determination
PIM2 was concentrated to 11 mg/ml in the presence of
compound 1 which was added to an initial concentration of
0.6 mM (from a 10 mM stock solution in DMSO). Crystals
were grown at 4uCi n1 . 5ml sitting drops mixing 0.3 mlP I M 2
with 1.2 mlm o t h e rl i q u o r( 9 0m MH E P E Sp H7 . 5 ,1 . 4 4MN a /
KPO4) and cryo-protected in mother liquor containing 30%
glycerol.
PIM2 diffraction data were collected on a flash-cooled crystal
(100 K) at the Swiss Light Source beamline SLS X10SA. Images
were indexed and integrated using MOSFLM, and scaled using
SCALA implemented in the CCP4 suite of programs. The
structure was solved by molecular replacement using the program
Phaser with the coordinates of PIM1 in complex with BIM1
(Protein Data Bank (PDB) code 1XWS). REFMAC5 was used for
refinement with iterative rounds of rigid-body refinement and
restrained refinement with TLS, against maximum likelihood
targets, interspersed with manual rebuilding of the model using
Xfit/XtalView.
Coordinates for the PIM2-inhibitor complex have been
deposited in the Protein Data Bank (PDB code 2IWI).
Measurement of Protein Kinase Inhibition
The synthesis of all compounds has been reported recently
[26,27]. PIM kinases (human) and substrate were purchased
from Upstate Biotechnology USA. 10 nM concentrations of
staurosporine or compounds 1–15 were incubated at room
temperature in 20 mM MOPS, 30 mM MgCl2,0 . 8mg/mLB S A ,
5% DMSO (resulting from the inhibitor stock solution), pH 7.0,
in the presence of substrate (50 mM S6 kinase/Rsk2 substrate
peptide 2) and kinase (3.3 nM PIM1, 1.5 nM PIM2). After 15
minutes, the reaction was initiated by adding ATP to a final
concentration of 100 mM, including approximately 0.2 mCi/mL
[c-
32P]ATP. Reactions were performed in a total volume of
25 mL. After 45 minutes, the reaction was terminated by spotting
17.5 mL on a circular P81 phosphocellulose paper (2.1 cm
diameter, Whatman), followed by washing four times (5 minutes
each wash) with 0.75% phosphoric acid and once with acetone.
The dried P81 papers were transferred to a scintillation vial, and
5 mL of scintillation cocktail was added, and the counts per
minute (CPM) were determined with a Beckmann 6000
scintillation counter. Each compound was measured in dupli-
cate. Percent activity was calculated by dividing the averaged
CPM for each compound by the control sample, corrected by
the background.
Note
For further details about this kinase strutcure, please refer to
SGC Material and Methods entry for PIM2.
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